CAMK2G and hydrops fetalis: Clinical gene therapy trials are already ongoing targeting PP1 (ClinicalTrials.gov ID; NCT05598333) and CaMKII (ClinicalTrials.gov ID; NCT02557217), the outcome of these trials will determine the potential of modulating phosphatases and kinases in HF.